齐鲁晚报·齐鲁壹点记者于中国证券监督管理委员会山东监管局官网（下称"山东证监局"）了解到，7月4日，该局就数字人（835670.BJ）财务核算不规范、 内部控制不完善等问题公示了相关监管措施，文号为行政监管措施决定书〔2025〕54号。 | 中国证券监督管理委员会 CHINA SECURITIES REGULATORY COMMISSION | | 山东省局 | | | 请输入关键字 | | | --- | --- | --- | --- | --- | --- | --- | | 首页 证监局介绍 | 辖区监管动态 | 政务信息 | 办事服务 | 辖区数据 | 互动交流 | 专题专栏 | | ♀ 当前位置：首页 > 政务信息 > 主动公开目录 > 证监局文科裁 > 行政监管措施 | | | | | | | | 索 引 号 bm56000001/2025-00008125 | | | | ਜੋ જેટ | 行政监管措施;上市公司监管 | | | 发布机构 | | | | 发文日期 | 2025年06月30日 | | | 名 称 关于对山东数字人科技股份有限公司采取责令改正、出具警示函措施的决定 | | | | ...

年 XR Copyright © 2025 头豹 / / / XR设备： 从技术突破到医疗影像新革命，解码体内影像"数字眼" 头豹词条报告系列 吕佳睿 · 头豹分析师 2025-05-30 未经平台授权，禁止转载 行业分类： 摘要 X射线成像（XR）设备广泛应用于医疗、安检、工业等领域，尤其在医疗领域是诊断疾病的基础设备。未来，XR设备将向智能化、低剂量化、高精度化发展。政策推动国 产替代加速，本土企业崛起。基层医疗服务能力评价指南等政策提升基层医疗机构对XR设备的需求，心血管疾病高发与PCI手术增长也推动市场规模扩张。未来，国家发改 委设备更新政策、县域医共体建设、西部地区政策倾斜及老龄化等因素将共同推动XR设备市场规模持续增长。 X射线成像（XR）设备是利用X射线穿透物体，基于不同组织对X射线吸收与衰减差异来获取物体内部影像信息的设备。当下，它广泛应用于 医疗、安检、工业等领域，在医疗领域，更是诊断胸部、骨关节、乳腺等多部位疾病的基础设备。未来，X射线成像设备将朝着智能化、低剂量 化、高精度化方向发展，AI技术融入将提升诊断效率与准确性，降低辐射剂量技术研发可减少对人体危害，设备分辨率和成像精度也会进一步 ...

Summary of Yirui Technology Conference Call Company Overview - **Company**: Yirui Technology - **Year**: 2024 - **Industry**: Medical Imaging and Industrial Detection Key Points Financial Performance - **2024 Revenue**: 18.3 billion, a slight decrease of 1.7% year-on-year [2][3] - **Net Profit**: 4.65 billion, down 23.4% year-on-year; Non-recurring net profit: 4.39 billion, down 25.8% year-on-year [3] - **Core Business Growth**: Core components revenue increased by approximately 50% to 1.26 billion; Solutions and technical services revenue surged by about 260% to 960 million [2][3] - **Gross Margin**: 50%, down six percentage points year-on-year due to changes in sales structure, slight price reductions in detectors, production cost fluctuations, and accounting adjustments [2][3] Market Dynamics - **Weak Demand**: Domestic medical, dental, and industrial end markets showed weak demand, leading to a 12% decline in detector business [2][3] - **R&D Investment**: R&D expenses reached 310 million, an increase of 50 million year-on-year, with significant progress in product expansion [2][3] - **2025 Q1 Performance**: Revenue remained stable at 4.8 billion; net profit increased by 2.7% to 1.43 billion; non-recurring net profit decreased by 9.2% [5] Strategic Initiatives - **Response to Tariffs**: Established factories in Korea and the U.S. to mitigate the impact of U.S. tariffs; shifting export orders to these locations [2][7][8] - **Domestic Market Opportunities**: The increase in domestic production due to tariffs is beneficial for the company in the high-end X-ray medical imaging sector [8][9] Product Development - **CT Tube Development**: Completed prototype development for CT tubes, currently in client testing phase; significant progress in CT detector core components [10][11] - **Vertical Integration**: Achieved batch delivery in core components like CT ceramics and PD collimators, enhancing competitiveness [4][14] Future Outlook - **2025 Revenue Growth Target**: Aiming for a 20% revenue growth despite uncertainties in domestic medical policies and market recovery [2][5] - **Market Share Goals**: Current global market share is approximately 20%, with a mid-term target of 50% and a long-term goal of over 70% [17] - **Focus on High-End Products**: Plans to increase market share in high-end products, particularly in the medical imaging sector [17] Challenges and Risks - **Trade Tensions**: U.S.-China trade tensions pose risks but also create opportunities for domestic market growth [8][9] - **Economic Factors**: Economic conditions and geopolitical factors have affected overseas revenue, with expectations for gradual recovery in new projects [16] Additional Insights - **Supply Chain Strategy**: Emphasizing vertical integration to enhance supply chain efficiency and product delivery [4][14] - **Collaboration with Major Clients**: Engaging with large clients to boost brand strength and market share, particularly in high-end medical equipment [17][22] Conclusion Yirui Technology is navigating a challenging market environment with strategic initiatives aimed at growth through innovation, market expansion, and operational efficiency. The company is well-positioned to leverage domestic opportunities while addressing the impacts of international trade dynamics.

1月22日，汕头市超声仪器研究所股份有限公司（股票代码：301602 简称：超研股份）将在深交所创业板上 市。作为国内超声诊断设备三巨头中成立时间最早的企业，超研股份已走过四十多个春秋，其发展历程正是中 国超声诊断设备自主创新不断发展的缩影。如今，随着医疗、基建相关重大设备"进口替代"进程的加快，以超 研股份为代表的国产超声诊断及工业检测设备厂商正迎来更加广阔的发展空间。 国产超声设备先驱，横跨医疗、工业两大领域 1. 中国医学超声鼻祖，超声影像设备销量排名前三 超研股份成立于1982年，公司前身超声研究所则成立于1978年，是国内唯一一家长期专注于超声设备及无损检 测设备开发的独立研究机构。 医学影像设备主要包括超声、X 射线、CT、MRI 和 PET。其中 超声医学影像设备 （B 超和全数字彩超）及 X 射线设备 （包括 CR、DR 设备等）应用最为广泛，行业内这两种设备占据了医学影像设备约30%以上的市场 份额。 我国医学影像设备行业起步较晚，直到1983年才出现第一台自主研制并量产的B超设备"中华B超"，其正是出 自超研股份之手，因此将超研股份称为中国医学超声鼻祖并不为过。 经过多年发展， 超研股份已 ...